Open AccessCase report: MPN-eo with balanced rearrangement of MPRIP-PDGFRB t(5;17)(q32;p11), responding to low dose imatinib
Author(s) -
Karolien Beel,
Geneviève Ameye,
Wim De Kelver,
Lucienne Michaux
Publication year - 2021
Publication title -
discussion of clinical cases
Language(s) - English
Resource type - Journals
eISSN - 2375-8449
pISSN - 2375-8473
DOI - 10.5430/dcc.v8n3p1
Subject(s) - pdgfrb , imatinib , myeloproliferative neoplasm , fusion gene , gene rearrangement , medicine , cancer research , genetics , gene , biology , bone marrow , myeloid leukemia , myelofibrosis
We present a young patient with a rare eosinophilic myeloproliferative neoplasm MPN-eo with a balanced rearrangement of MPRIP-PDGFRB t(5;17)(q32;p11). This fusion gene was reported in only one other case in 2015. A personalized molecular test was developed with the diagnostic material of the patient. Our patient is in complete cytogenetic and molecular remission under low dose imatinib, two years after treatment initiation.